Cancer

• Breast
  • ATNEC – Axillary management in T1-3 N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy
  • EndoNET – Randomised controlled trial evaluating effectiveness of neoadjuvant endocrine treatment in post-menopausal women
  • OPTIMA – Optimal Personalised Treatment of early breast cancer using Multiparameter Analysis
  • POETIC-A – PreOperative Endocrine Therapy for Individualised Care with Abemaciclib
  • ROSETA – Refining and Optimising a behavioural intervention to Support Endocrine Therapy Adherence: The ROSETA Optimisation Trial
  • SMALL – A Phase 3, randomised, multi-centre trial addressing overtreatment of small screen-detected breast cancer by comparing standard surgery versus minimally invasive vacuum-assisted excision
  • SWEET – Supporting Women with adhErence to hormonE Therapy following breast cancer
• Haematology
  • ALLTogether1 – A treatment study protocol of the Altogether consortium for children and young adults (0-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)
  • PETReA – Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma
  • RADAR – Myeloma XV – Risk-Adapted therapy Directed According to Response comparing treatment escalation and de-escalation strategies in newly diagnosed patients with multiple myeloma (NDMM) suitable for stem cell transplant (TE)
  • STATIC – A Randomised Phase III Trial Comparing Intermittent with Continuous Treatment Strategies in Chronic Lymphocytic Leukaemia (CLL)
  • The Molecular Investigation of Unexplained Anaemias – The Molecular Investigation of Unexplained Anaemias and Related Congenital Anaemias
• Gastrointestinal/Gynaecology
  • Add-Aspirin – A phase III double-blind placebo-controlled randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours
  • ARIEL – A biomarker enrichment trial of anti-EGFR agents in patients with advanced colorectal cancer (aCRC) with wild[1]type RAS and right primary tumour location (right-PTL)
  • FOxTROT Platform – Personalising neo-adjuvant chemotherapy in locally advanced but operable colon cancer. A randomised trial programme
    • FOxTROT, FOxTROT 2, FOxTROT 3, FOxTROT 4
  • PRECISION PANC – Advancing personalised medicine treatment strategies for pancreatic cancer
  • PRIMUS-001 – An adaptive phase II study of FOLFOX-A (FOLFOX and nab-paclitaxel) versus AG (nab-paclitaxel and gemcitabine) in patients with metastatic pancreatic cancer, with integrated biomarker evaluation
  • TRACC C – Tracking mutations in cell free tumour DNA to predict Relapse in eArly Colorectal Cancer
• Urology
  • IP2-ATLANTA – Additional Treatments to the Local tumour for metastatic prostate cancer: Assessment of Novel Treatment Algorithms

• Share:
• Facebook
• Twitter
• LinkedIn